Amadix is focused on developing innovative blood-based tests for the early detection of various types of cancer, including lung, colorectal, and pancreatic cancers. Their flagship products include DiagnoLung®, a minimally invasive test aimed at early lung cancer detection, and PreveCol®, which utilizes a high-precision algorithm that combines biomarkers with individual clinical characteristics for colorectal cancer screening. PreveCol® has received CE marking and is recognized as a Breakthrough Device by the FDA, highlighting its potential to address significant clinical needs in cancer diagnostics. PancreaDix® is also under clinical validation, targeting the early diagnosis of pancreatic cancer through blood testing.

The company emphasizes the importance of personalized and precision medicine, utilizing specific biomarkers to enhance cancer diagnosis and treatment planning. Amadix is also leveraging advanced data analytics and artificial intelligence to explore clinical records and patient lifestyle data, aiming to identify new risk factors and develop predictive models that can improve patient outcomes. Their commitment to innovation in cancer diagnostics is further supported by a team of experienced professionals and a scientific advisory board, ensuring that their products not only meet clinical needs but also contribute to the overall improvement of patient survival and quality of life.

Spain

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood.

The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

Amadix

Company Details